Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A double-blind, placebo-controlled study in Huntington's disease patients to determine the safety and tolerability of selisistat (SEN0014196)
2011-001131-23Phase 2Completed
- Sponsor
- Siena Biotech
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Selisistat in Huntington disease (HD) (3 arms), sponsored by Siena Biotech. Primary endpoint: Safety and tolerability over 12 weeks. Started Jun 2011; status: completed.
02
Drugs
Selisistat
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2011-001131-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001131-23.